20. Enterprise-wide Disclosures

Geographic Area Information

Revenues, including license fees, royalties, grant income, and other revenues by geographic area are based on the country of domicile of the licensee or grantor.

Geographic Area	Revenues for the Year ending December 31,
	2012		2011		2010

Domestic	$	2,529,669	$	3,059,810	$	3,311,211
Asia		1,385,658		1,374,349		396,807
Total revenues	$	3,915,327	$	4,434,159	$	3,708,018

Major Sources of Revenues

BioTime has three major customers and three major grants comprising significant amounts of total revenues.

All of BioTime's royalty revenues were generated through sales of Hextend® by Hospira in the U.S. and by CJ in the Republic of Korea. BioTime also earned license fees from CJ and Summit.

BioTime was awarded a $4,721,706 grant for a stem cell research project related to its ACTCellerate™ technology by CIRM in April 2009. The CIRM grant covers the period of September 1, 2009 through August 31, 2012, and as of December 31, 2012 and 2011, BioTime had received payments from CIRM totaling $392,665 and $1,570,663, respectively. BioTime recognized $1,047,106and $1,570,663 as revenues as of December 31, 2012 and 2011, respectively.The final quarterly installment of $392,664 was collected in February 2013.

During 2012, BioTime also received $45,645 and recognized as revenues $47,507 of a $335,900grant awarded by the NIH. The grant started on September 30, 2011 and originally ended on September 29, 2012. However, this grant was extended through September 29, 2013.

During 2012, grant income also included awards from other sources in the amount of $1,109,699 recognized through Cell Cure Neurosciences and $18,145 through Life Map Sciences, Ltd.

During 2012, BioTimereceived $1,222,516 and recognized $373,798 (net of $379,098 in royalty and commission fees) in net subscription and advertisement revenues through LifeMap Sciences.

The following table shows the relative portions of BioTime's Hextend® and PentaLyte® royalty and license fee revenues paid by Hospira, CJ, and Summitthat were recognized during the years ended December 31, 2012, 2011, and 2010, the subscription and advertisement revenues, and the OCS, CIRM and QTDP grant incomerecognized during the same periods:

Sources of Revenues	% of Total Revenues for Year ended December 31,
	2012		2011		2010
Hospira		11.0%		14.2%		22.7%
CJ		2.9%		3.5%		6.8%
Summit		3.7%		3.3%		3.9%
CIRM		26.7%		35.4%		42.5%
QTDP		-		-		19.8%
OCS		26.0%		23.0%		-
Others		29.7%		20.6%		4.3%